PRAC recommends restricting use to relapsing remitting MS that is highly active despite adequate treatment with ≥ 1 disease-modifying therapy, or if disease is worsening rapidly with at ≥ 2 disabling relapses in a year and brain-imaging showing new damage. Also, alemtuzumab must also no longer be used in patients with certain heart, circulation or bleeding disorders or in patients who have auto-immune disorders other than MS.